Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.43 |
| ▸ | PTGES | O14684 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.38 |
| ▸ | CYP2E1 | P05181 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | CYP2C8 | P10632 | 3/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.38 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.38 |
| ▸ | G6PD | P11413 | 1/20 | 0.37 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8834767 | 0.67 | GPR84 (0.37) | GPR84CYP2C9CYP2C19CYP1A2CYP2E1 | |
| SCHEMBL7225374 | 0.67 | GPR84 (0.43) | GPR84PTGESMAPTCYP2C9CYP2C19 | |
| SCHEMBL11032057 | 0.64 | GPR84 (0.39) | GPR84MAPTCYP2C9CYP2C19SOAT1 | |
| SCHEMBL5316867 | 0.64 | PTGS2 (0.66) | G6PDSOAT1PTGS2 | |
| SCHEMBL11334284 | 0.63 | SMN1; SMN2 (0.51) | GPR84MAPTCYP2C9CYP2C19CYP1A2 | |
| SCHEMBL7298064 | 0.63 | GPR84 (0.37) | GPR84MAPTCYP2C9CYP2C19G6PD | |
| SCHEMBL7260314 | 0.63 | PTGES (0.55) | PTGESMAPTCYP2C9CYP2C19CYP1A2 | |
| SCHEMBL20495338 | 0.63 | PTGES (0.55) | PTGESMAPTCYP2C9CYP2C19CYP1A2 | |
| SCHEMBL5315774 | 0.63 | PTGES (0.55) | PTGESMAPTCYP2C9CYP2C19CYP1A2 | |
| SCHEMBL6022136 | 0.63 | ALOX15 (0.51) | GPR84PTGESMAPTSMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6509362-B2 | Cholesteryl acyl transferase (ACAT) inhibitors; treatment of hyperlipidaemia and atherosclerosis. | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2003-01-21 | — | — | US | claimed |
| US-20020068739-A1 | New N-phenylamide and N-pyridylamide derivatives, method of preparing them and pharmaceutical compositions containing them | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2002-06-06 | — | — | US | claimed |
| US-6339097-B1 | FOR THERAPY OF HYPERLIPIDAEMIA AND ATHEROSCLEROSIS; CHOLESTERYL ACYL TRANSFERASE (ACAT) INHIBITORS | MERCK PATENT GMBH (DE) | 2002-01-15 | — | — | US | claimed |
| EP-1040109-A1 | N-PHENYLAMIDE AND N-PYRIDYLAMIDE DERIVATIVES, METHOD OF PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MERCK PATENT GmbH (DE) | 2000-10-04 | — | — | EP | claimed |
| WO-1999033825-A1 | N-PHENYLAMIDE AND N-PYRIDYLAMIDE DERIVATIVES, METHOD OF PREPARING THEM AND PHARMACEUTICAL COMPOSITONS CONTAINING THEM | MERCK PATENT GMBH (DE) | 1999-07-08 | — | — | WO | claimed |
| US-6509362-B2 | Cholesteryl acyl transferase (ACAT) inhibitors; treatment of hyperlipidaemia and atherosclerosis. | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2003-01-21 | — | — | US | disclosed |
| US-20020068739-A1 | New N-phenylamide and N-pyridylamide derivatives, method of preparing them and pharmaceutical compositions containing them | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2002-06-06 | — | — | US | disclosed |
| US-6339097-B1 | FOR THERAPY OF HYPERLIPIDAEMIA AND ATHEROSCLEROSIS; CHOLESTERYL ACYL TRANSFERASE (ACAT) INHIBITORS | MERCK PATENT GMBH (DE) | 2002-01-15 | — | — | US | disclosed |
| EP-1040109-A1 | N-PHENYLAMIDE AND N-PYRIDYLAMIDE DERIVATIVES, METHOD OF PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MERCK PATENT GmbH (DE) | 2000-10-04 | — | — | EP | disclosed |
| WO-1999033825-A1 | N-PHENYLAMIDE AND N-PYRIDYLAMIDE DERIVATIVES, METHOD OF PREPARING THEM AND PHARMACEUTICAL COMPOSITONS CONTAINING THEM | MERCK PATENT GMBH (DE) | 1999-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068739-A1 | New N-phenylamide and N-pyridylamide derivatives, method of preparing them and pharmaceutical compositions containing them | ACAT2, LCAT, ACAT1 | GPR84 2969/4885PTGES 1279/4885MAPT 893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.